Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer: A Prospective Explorative Study

Trial Profile

Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer: A Prospective Explorative Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 May 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 01 May 2017 Results of a sub-study assessing FDG PET/CT scans (n=40) published in the European Journal of Nuclear Medicine and Molecular Imaging
    • 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research
    • 26 Mar 2016 Planned End Date changed from 1 Aug 2015 to 1 May 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top